Gilteritinib (XOSPATA®) in Turkey: Early Access Program Results

BACKGROUND AND OBJECTIVES: Gilteritinib (XOSPATA®, Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor, involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ADMIRAL trial, gilteritinib was compared with the standard of care in (R/R) acute mye...

Descripción completa

Detalles Bibliográficos
Autores principales: Dogu, Mehmet Hilmi, Tekgunduz, Ali Irfan Emre, Deveci, Burak, Korkmaz, Gulten, Comert, Melda, Sevindik, Omur Gokmen, Yokus, Osman, Serin, Istemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171205/
https://www.ncbi.nlm.nih.gov/pubmed/37180209
http://dx.doi.org/10.4084/MJHID.2023.031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171205/
https://www.ncbi.nlm.nih.gov/pubmed/37180209
http://dx.doi.org/10.4084/MJHID.2023.031

Ejemplares similares